Mutated or dysregulated transcription factors represent a unique class of drug targets that
mediate aberrant gene expression, including blockade of differentiation and cell death gene …

Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

Background Apalutamide, a competitive inhibitor of the androgen receptor, is under
development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide …

Background The phase 3 SPARTAN study evaluated apalutamide versus placebo in
patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate …

Prostate cancer is a global health problem, but incidence varies considerably across
different continents. Asia is traditionally considered a low-incidence area, but the incidence …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Due to the constantly increasing number of cases, prostate cancer has become one of the
most important health problems of modern societies. This review presents the current …

Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …

Transcription factors (TFs) are indispensable for the modulation of various signaling
pathways associated with normal cell homeostasis and disease conditions. Among cancer …